Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,462,992
  • Shares Outstanding, K 1,478,332
  • Annual Sales, $ 32,753 M
  • Annual Income, $ 5,687 M
  • 60-Month Beta 1.10
  • Price/Sales 3.54
  • Price/Cash Flow 8.39
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.21
  • Number of Estimates 6
  • High Estimate 2.23
  • Low Estimate 2.19
  • Prior Year 2.00
  • Growth Rate Est. (year over year) +10.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.81 +6.18%
on 06/03/19
80.10 -2.16%
on 05/28/19
-1.69 (-2.11%)
since 05/24/19
3-Month
73.81 +6.18%
on 06/03/19
84.73 -7.51%
on 04/03/19
-1.39 (-1.74%)
since 03/22/19
52-Week
73.81 +6.18%
on 06/03/19
100.23 -21.81%
on 08/20/18
-15.12 (-16.17%)
since 06/22/18

Most Recent Stories

More News
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on CANOVA (M13-494),...

ABBV : 78.43 (-0.44%)
Forget Bargain Hunting: Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

SCVL : 28.16 (+3.38%)
CRTO : 18.06 (-1.90%)
CROX : 19.24 (-0.62%)
EAT : 37.30 (-1.51%)
ABBV : 78.43 (-0.44%)
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

NVO : 51.28 (+0.87%)
MRK : 85.51 (+1.11%)
NVS : 92.79 (+0.32%)
ABBV : 78.43 (-0.44%)
Top Ranked Income Stocks to Buy for June 21st

Top Ranked Income Stocks to Buy for June 21st

ABR : 12.17 (-0.81%)
CNA : 47.18 (+0.13%)
ABBV : 78.43 (-0.44%)
BDGE : 27.83 (-2.76%)
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

MRK : 85.51 (+1.11%)
ABBV : 78.43 (-0.44%)
REGN : 312.74 (-2.35%)
SNY : 43.79 (-0.82%)
AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share.

ABBV : 78.43 (-0.44%)
AbbVie's MAVIRET(TM) now listed on the Nova Scotia and Manitoba formularies

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET(TM) (glecaprevir/pibrentasvir tablets) is now listed on the Nova Scotia Formulary and...

ENTA : 82.75 (-4.36%)
ABBV : 78.43 (-0.44%)
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

AZN : 41.48 (+0.29%)
MRK : 85.51 (+1.11%)
ABBV : 78.43 (-0.44%)
RHHBY : 35.3900 (-0.59%)
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

PRTY : 6.70 (-4.29%)
PULM : 0.96 (-1.03%)
HPQ : 20.65 (-0.24%)
ONCS : 2.58 (-3.37%)
ABBV : 78.43 (-0.44%)
AbbVie to Present at the Goldman Sachs Global Healthcare Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Michael Severino, vice...

ABBV : 78.43 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 80.75
1st Resistance Point 79.76
Last Price 78.43
1st Support Level 77.11
2nd Support Level 75.45

See More

52-Week High 100.23
Fibonacci 61.8% 90.14
Fibonacci 50% 87.02
Fibonacci 38.2% 83.90
Last Price 78.43
52-Week Low 73.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar